Join Sona Nanotech CEO David Regan and CMO Dr. Carman Giacomantonio for a live investor webinar during which they will discuss the first dosing of a patient in Sona’s first-in-human clinical trial of its targeted hyperthermia cancer therapy, and outline the implications for its clinical development pathway.